Factor X deletion mutants and analogues thereof

US6562598B1 · kind B1 · utility

Assignee

• Baxter Aktiengesellschaft · AT

Inventors

• Michele Himmelspach · Port, CH
• Michael Pfleiderer · Darmstadt, DE
• Falko-Guenter Falkner · Orth an der Donau, AT
• Johann Eibl · Wien, AT
• Friedrich Dorner · Wien, AT
• Uwe Schlokat · Orth an der Donau, AT

Key dates

• Filing date: Nov 18, 1999
• Grant date: May 13, 2003
• Expiry date: Nov 18, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.